{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:10:27Z","timestamp":1789564227340,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1131932"],"award-info":[{"award-number":["GNT1131932"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3452-y","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T12:03:54Z","timestamp":1560427434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["CASSETTE\u2014clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation: study protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3379-6135","authenticated-orcid":false,"given":"Ravindra","family":"Dotel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Y. C.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane N.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew V. N.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita J.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan J.","family":"McMullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua R.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon P.","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,13]]},"reference":[{"key":"3452_CR1","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1473-3099(05)70295-4","volume":"5","author":"HFL Wertheim","year":"2005","unstructured":"Wertheim HFL, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005;5:751\u201362.","journal-title":"Lancet Infect Dis"},{"key":"3452_CR2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1128\/MMBR.27.1.56-71.1963","volume":"27","author":"RE Williams","year":"1963","unstructured":"Williams RE. Healthy carriage of Staphylococcus aureus: its prevalence and importance. Bacteriol Rev. 1963;27:56\u201371.","journal-title":"Bacteriol Rev"},{"key":"3452_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/bmj.38834.421713.2F","volume":"333","author":"DH Wyllie","year":"2006","unstructured":"Wyllie DH, Crook DW, Peto TEA. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ. 2006;333:281.","journal-title":"BMJ"},{"key":"3452_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/CMR.05022-11","volume":"25","author":"SJ van Hal","year":"2012","unstructured":"van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012;25:362\u201386.","journal-title":"Clin Microbiol Rev"},{"key":"3452_CR5","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapediatrics.2016.1477","volume":"170","author":"BJ McMullan","year":"2016","unstructured":"McMullan BJ, Bowen A, Blyth CC, Van Hal S, Korman TM, Buttery J, et al. Epidemiology and mortality of Staphylococcus aureus bacteremia in Australian and New Zealand children. JAMA Pediatr. 2016;170:979\u201386.","journal-title":"JAMA Pediatr"},{"key":"3452_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0140-6736(02)07877-7","volume":"359","author":"Y Gillet","year":"2002","unstructured":"Gillet Y, Issartel B, Vanhems P, Fournet J-C, Lina G, Bes M, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet (London, England). 2002;359:753\u20139.","journal-title":"Lancet (London, England)"},{"key":"3452_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1086\/519263","volume":"45","author":"Y Gillet","year":"2007","unstructured":"Gillet Y, Vanhems P, Lina G, Bes M, Vandenesch F, Floret D, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis. 2007;45:315\u201321.","journal-title":"Clin Infect Dis"},{"key":"3452_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SYC Tong","year":"2015","unstructured":"Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VGJ. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28:603\u201361.","journal-title":"Clin Microbiol Rev"},{"key":"3452_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJM200101043440102","volume":"344","author":"C von Eiff","year":"2001","unstructured":"von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001;344:11\u20136.","journal-title":"N Engl J Med"},{"key":"3452_CR10","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1093\/cid\/civ120","volume":"60","author":"AD Bai","year":"2015","unstructured":"Bai AD, Showler A, Burry L, Steinberg M, Ricciuto DR, Fernandes T, et al. Impact of infectious disease consultation on quality of care, mortality, and length of stay in Staphylococcus aureus bacteremia: results from a large multicenter cohort study. Clin Infect Dis. 2015;60:1451\u201361.","journal-title":"Clin Infect Dis"},{"key":"3452_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jinf.2015.09.037","volume":"72","author":"M Vogel","year":"2016","unstructured":"Vogel M, Schmitz RPH, Hagel S, Pletz MW, Gagelmann N, Scherag A, et al. Infectious disease consultation for Staphylococcus aureus bacteremia\u2014a systematic review and meta-analysis. J Infect. 2016;72:19\u201328.","journal-title":"J Infect"},{"key":"3452_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285\u201392.","journal-title":"Clin Infect Dis"},{"key":"3452_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S1473-3099(10)70285-1","volume":"11","author":"GE Thwaites","year":"2011","unstructured":"Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Torok ME, et al. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis. 2011;11:208\u201322.","journal-title":"Lancet Infect Dis"},{"key":"3452_CR14","unstructured":"eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; 2015."},{"key":"3452_CR15","unstructured":"Health Protection Agency (UK). Guidance on the diagnosis and management of PVL-associated Staphylococcus aureus infections (PVL-SA) in England. 2nd edition. 2008."},{"key":"3452_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ijantimicag.2011.05.003","volume":"38","author":"Y Gillet","year":"2011","unstructured":"Gillet Y, Dumitrescu O, Tristan A, Dauwalder O, Javouhey E, Floret D, et al. Pragmatic management of Panton-Valentine leukocidin-associated staphylococcal diseases. Int J Antimicrob Agents. 2011;38:457\u201364.","journal-title":"Int J Antimicrob Agents"},{"key":"3452_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkz157","volume":"74","author":"AJ Campbell","year":"2019","unstructured":"Campbell AJ, Dotel R, Blyth CC, Davis JS, Tong SYC, Bowen AC. Adjunctive protein synthesis inhibitor antibiotics for toxin suppression in Staphylococcus aureus infections: a systematic appraisal. J Antimicrob Chemother. 2019;74:1\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"3452_CR18","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJM199808203390806","volume":"339","author":"FD Lowy","year":"1998","unstructured":"Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520\u201332.","journal-title":"N Engl J Med"},{"key":"3452_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1128\/CMR.13.1.16","volume":"13","author":"MM Dinges","year":"2000","unstructured":"Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev. 2000;13:16\u201334 table of contents.","journal-title":"Clin Microbiol Rev"},{"key":"3452_CR20","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/nrmicro1289","volume":"3","author":"TJ Foster","year":"2005","unstructured":"Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol. 2005;3:948\u201358.","journal-title":"Nat Rev Microbiol"},{"key":"3452_CR21","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1128\/JCM.41.4.1434-1439.2003","volume":"41","author":"K Becker","year":"2003","unstructured":"Becker K, Friedrich AW, Lubritz G, Weilert M, Peters G, Von Eiff C. Prevalence of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus aureus isolated from blood and nasal specimens. J Clin Microbiol. 2003;41:1434\u20139.","journal-title":"J Clin Microbiol"},{"key":"3452_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1128\/CMR.00104-12","volume":"26","author":"AR Spaulding","year":"2013","unstructured":"Spaulding AR, Salgado-Pabon W, Kohler PL, Horswill AR, Leung DYM, Schlievert PM. Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev. 2013;26:422\u201347.","journal-title":"Clin Microbiol Rev"},{"key":"3452_CR23","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.1128\/IAI.70.9.4987-4996.2002","volume":"70","author":"SJ Peacock","year":"2002","unstructured":"Peacock SJ, Moore CE, Justice A, Kantzanou M, Story L, Mackie K, et al. Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus. Infect Immun. 2002;70:4987\u201396.","journal-title":"Infect Immun"},{"key":"3452_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1186\/s12879-016-1698-5","volume":"16","author":"S Hewagama","year":"2016","unstructured":"Hewagama S, Spelman T, Woolley M, McLeod J, Gordon D, Einsiedel L. The epidemiology of Staphylococcus aureus and Panton-Valentine leucocidin (PVL) in Central Australia, 2006-2010. BMC Infect Dis England. 2016;16:382.","journal-title":"BMC Infect Dis"},{"key":"3452_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/jac\/dkm206","volume":"60","author":"MJ Ellington","year":"2007","unstructured":"Ellington MJ, Hope R, Ganner M, Ganner M, East C, Brick G, et al. Is Panton-Valentine leucocidin associated with the pathogenesis of Staphylococcus aureus bacteraemia in the UK? J Antimicrob Chemother. 2007;60:402\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"3452_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(12)70238-4","volume":"13","author":"LJ Shallcross","year":"2013","unstructured":"Shallcross LJ, Fragaszy E, Johnson AM, Hayward AC. The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:43\u201354.","journal-title":"Lancet Infect Dis"},{"key":"3452_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-2180-14-31","volume":"14","author":"KYL Chua","year":"2014","unstructured":"Chua KYL, Monk IR, Lin Y-H, Seemann T, Tuck KL, Porter JL, et al. Hyperexpression of alpha-hemolysin explains enhanced virulence of sequence type 93 community-associated methicillin-resistant Staphylococcus aureus. BMC Microbiol. 2014;14:31.","journal-title":"BMC Microbiol"},{"key":"3452_CR28","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/j.1469-0691.2009.02732.x","volume":"15","author":"SYC Tong","year":"2009","unstructured":"Tong SYC, Lilliebridge RA, Holt DC, McDonald MI, Currie BJ, Giffard PM. High-resolution melting analysis of the spa locus reveals significant diversity within sequence type 93 methicillin-resistant Staphylococcus aureus from northern Australia. Clin Microbiol Infect. 2009;15:1126\u201331.","journal-title":"Clin Microbiol Infect"},{"key":"3452_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/toxins8030072","volume":"8","author":"C Kong","year":"2016","unstructured":"Kong C, Neoh H, Nathan S. Targeting Staphylococcus aureus toxins: a potential form of anti-virulence therapy. Toxins (Basel). 2016;8:72.","journal-title":"Toxins (Basel)"},{"key":"3452_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1086\/648673","volume":"50","author":"NJ Verkaik","year":"2010","unstructured":"Verkaik NJ, Dauwalder O, Antri K, Boubekri I, de Vogel CP, Badiou C, et al. Immunogenicity of toxins during Staphylococcus aureus infection. Clin Infect Dis. 2010;50:61\u20138.","journal-title":"Clin Infect Dis"},{"key":"3452_CR31","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/nrmicro1265","volume":"3","author":"J Poehlsgaard","year":"2005","unstructured":"Poehlsgaard J, Douthwaite S. The bacterial ribosome as a target for antibiotics. Nat Rev Microbiol. 2005;3:870\u201381.","journal-title":"Nat Rev Microbiol"},{"key":"3452_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3109\/10409230903307311","volume":"44","author":"DN Wilson","year":"2009","unstructured":"Wilson DN. The A-Z of bacterial translation inhibitors. Crit Rev Biochem Mol Biol. 2009;44:393\u2013433.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"3452_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.curtheres.2012.04.002","volume":"73","author":"BA Diep","year":"2012","unstructured":"Diep BA, Equils O, Huang DB, Gladue R. Linezolid effects on bacterial toxin production and host immune response: review of the evidence. Curr Ther Res Clin Exp. 2012;73:86\u2013102.","journal-title":"Curr Ther Res Clin Exp"},{"key":"3452_CR34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0002-9343(52)90293-3","volume":"13","author":"H Eagle","year":"1952","unstructured":"Eagle H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med. 1952;13:389\u201399.","journal-title":"Am J Med"},{"key":"3452_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/infdis\/158.1.23","volume":"158","author":"DL Stevens","year":"1988","unstructured":"Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158:23\u20138.","journal-title":"J Infect Dis"},{"key":"3452_CR36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1086\/510396","volume":"195","author":"DL Stevens","year":"2007","unstructured":"Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis. 2007;195:202\u201311.","journal-title":"J Infect Dis"},{"key":"3452_CR37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/infdis\/172.2.410","volume":"172","author":"DS Kernodle","year":"1995","unstructured":"Kernodle DS, McGraw PA, Barg NL, Menzies BE, Voladri RK, Harshman S. Growth of Staphylococcus aureus with nafcillin in vitro induces alpha-toxin production and increases the lethal activity of sterile broth filtrates in a murine model. J Infect Dis. 1995;172:410\u20139.","journal-title":"J Infect Dis"},{"key":"3452_CR38","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1128\/AAC.42.11.2817","volume":"42","author":"K Ohlsen","year":"1998","unstructured":"Ohlsen K, Ziebuhr W, Koller KP, Hell W, Wichelhaus TA, Hacker J. Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 1998;42:2817\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"3452_CR39","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1128\/AAC.01201-06","volume":"51","author":"O Dumitrescu","year":"2007","unstructured":"Dumitrescu O, Boisset S, Badiou C, Bes M, Benito Y, Reverdy M-E, et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother. 2007;51:1515\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"3452_CR40","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/j.1469-0691.2007.01947.x","volume":"14","author":"O Dumitrescu","year":"2008","unstructured":"Dumitrescu O, Badiou C, Bes M, Reverdy M-E, Vandenesch F, Etienne J, et al. Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect. 2008;14:384\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"3452_CR41","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1093\/jac\/dkt073","volume":"68","author":"MP Otto","year":"2013","unstructured":"Otto MP, Martin E, Badiou C, Lebrun S, Bes M, Vandenesch F, et al. Effects of subinhibitory concentrations of antibiotics on virulence factor expression by community-acquired methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2013;68:1524\u201332.","journal-title":"J Antimicrob Chemother"},{"key":"3452_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/01.PCC.0000149131.72248.E6","volume":"6","author":"B Goldstein","year":"2005","unstructured":"Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6:2\u20138.","journal-title":"Pediatr Crit Care Med"},{"key":"3452_CR43","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/INF.0000000000001926","volume":"37","author":"AC Arrieta","year":"2018","unstructured":"Arrieta AC, Bradley JS, Popejoy MW, Bensaci M, Grandhi A, Bokesch P, et al. Randomized multicenter study comparing safety and efficacy of daptomycin versus standard-of-care in pediatric patients with Staphylococcal bacteremia. Pediatr Infect Dis J. 2018;37:893\u2013900.","journal-title":"Pediatr Infect Dis J"},{"key":"3452_CR44","volume-title":"Antimicrobial dosing in renal impairment","author":"Children\u2019s Hospital at Westmead","year":"2015","unstructured":"Children\u2019s Hospital at Westmead. Antimicrobial dosing in renal impairment. 2015. \n                    http:\/\/www.schn.health.nsw.gov.au\/_policies\/pdf\/2012-8011.pdf\n                    \n                  . Accessed 6 July 2017."},{"key":"3452_CR45","first-page":"1644","volume-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM Consensus Conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine","author":"RC Bone","year":"1992","unstructured":"Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM Consensus Conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine. Chest, vol. 101; 1992. p. 1644\u201355."},{"key":"3452_CR46","unstructured":"Clinical Excellence Commission, New South Wales Government (Australia). Paediatric Patient Safety Pathways and Guidelines. Available on the webpage: \n                    http:\/\/www.cec.health.nsw.gov.au\/patient-safety-programs\/paediatric-patient-safety\/pqp-sepsis-kills\n                    \n                  . Accessed 30 Oct 2018."},{"key":"3452_CR47","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/cid\/cix287","volume":"65","author":"JS McDanel","year":"2017","unstructured":"McDanel JS, Roghmann M-C, Perencevich EN, Ohl ME, Goto M, Livorsi DJ, et al. Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study. Clin Infect Dis. 2017;65:100\u20136.","journal-title":"Clin Infect Dis"},{"key":"3452_CR48","volume-title":"Adelaide: Australian Medicines Handbook Pty Ltd","author":"Australian Medicines Handbook 2017 (online)","year":"2017","unstructured":"Australian Medicines Handbook 2017 (online). Adelaide: Australian Medicines Handbook Pty Ltd; 2017. Available from: \n                    https:\/\/amhonline.amh.net.au\n                    \n                  ."},{"key":"3452_CR49","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1. 2017."},{"key":"3452_CR50","unstructured":"National Health and Medical Research Council (NHMRC) Guidance: Safety Monitoring and Reporting in Clinical Trials Involving Therapeutic Goods (2016). \n                    https:\/\/www.nhmrc.gov.au\/sites\/default\/files\/images\/NHMRC-guidance-safety-monitoring-and-reporting.pdf"},{"key":"3452_CR51","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13063-016-1295-3","volume":"17","author":"SYC Tong","year":"2016","unstructured":"Tong SYC, Nelson J, Paterson DL, Fowler VGJ, Howden BP, Cheng AC, et al. CAMERA2\u2014combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. Trials. 2016;17:170.","journal-title":"Trials"},{"key":"3452_CR52","first-page":"E309","volume":"38","author":"GW Coombs","year":"2014","unstructured":"Coombs GW, Nimmo GR, Daly DA, Le TT, Pearson JC, Tan H-L, et al. Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013. Commun Dis Intell Q Rep. 2014;38:E309\u201319.","journal-title":"Commun Dis Intell Q Rep"},{"key":"3452_CR53","first-page":"E244","volume":"40","author":"GW Coombs","year":"2016","unstructured":"Coombs GW, Daley DA, Thin Lee Y, Pearson JC, Robinson JO, Nimmo GR, et al. Australian Group on Antimicrobial Resistance Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2014. Commun Dis Intell Q Rep. 2016;40:E244\u201354.","journal-title":"Commun Dis Intell Q Rep"},{"key":"3452_CR54","volume-title":"Staphpath 2017; 2017 25\u201326 February; Adelaide, Australia","author":"The Australian Group on Antimicrobial Resistance (AGAR) 2015 Australian Staphylococcus aureus Sepsis Outcome Program (ASSOP)","year":"2017","unstructured":"The Australian Group on Antimicrobial Resistance (AGAR) 2015 Australian Staphylococcus aureus Sepsis Outcome Program (ASSOP). Staphpath 2017; 2017 25\u201326 February; Adelaide, Australia; 2017."},{"key":"3452_CR55","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1086\/426894","volume":"40","author":"JS Lewis 2nd","year":"2005","unstructured":"Lewis JS 2nd, Jorgensen JH. Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis. 2005;40:280\u20135.","journal-title":"Clin Infect Dis"},{"key":"3452_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12941-018-0291-8","volume":"17","author":"E Hodille","year":"2018","unstructured":"Hodille E, Badiou C, Bouveyron C, Bes M, Tristan A, Vandenesch F, et al. Clindamycin suppresses virulence expression in inducible clindamycin-resistant Staphylococcus aureus strains. Ann Clin Microbiol Antimicrob. 2018;17:38.","journal-title":"Ann Clin Microbiol Antimicrob"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3452-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3452-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3452-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T19:37:10Z","timestamp":1591904230000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3452-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,13]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3452"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3452-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.265\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.265\/v2","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,13]]},"assertion":[{"value":"22 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent will be obtained from all study participants.The following ethics board have approved the study:","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"353"}}